Chevrier, Marc,Friemuth, William,Zhong, Zhenshao,Odenheimer, Daniel,Perkins, Melissa D.
申请号：
AU2013205399
公开号：
AU2013205399A1
申请日:
2013.04.23
申请国别(地区):
AU
年份:
2013
代理人:
摘要：
#$%^&*AU2013205399A120130523.pdf#####ABSTRACT The present invention relates to methods and compositions for use in treatment of patients with autoantibody positive disease. In a specific embodiment, the present invention relates to a method of treating a patient that has an ANA titer of 1:80 or greater and/or greater than or equal to 30 IU/ml of anti-dsDNA antibodies in his/her blood plasma or serum comprising administering a therapeutically effective amount of an immunomodulatory agent, such as an antagonist of Neutrokine-alpha. Additionally provided is a method of reducing the frequency and/or quantity of corticosteroid administration to patients. In preferred embodiments, the patient has systemic lupus erythematosus. Methods for determining if a lupus patient is responding to medical treatment are also provided.(UnD Lf0) :> 0) Oi. cooc CC 00 LC 0CD~ C co oz 0<0 (00 Al C 0 cUo 0 Mhe 1/1
